AG˹ٷ

STOCK TITAN

[Form 4] Viridian Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Ralliant Corp (RAL) filed a Form 4 disclosing that director Ganesh Moorthy acquired 4,434 restricted stock units (RSUs) of common stock on 06/30/2025. The RSUs were granted at no cost (price $0) and are classified under transaction code “A� (grant, award or other acquisition).

The award will vest on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to Ralliant’s 2026 annual shareholders� meeting. Following the grant, Moorthy’s total beneficial ownership stands at 4,434 shares, held directly. No derivative securities were reported, and the filing was executed by attorney-in-fact Sarah Johnson on 07/02/2025.

The transaction represents a routine annual equity grant meant to align director incentives with shareholder interests and does not, by itself, signal a change in the company’s financial outlook.

Ralliant Corp (RAL) ha presentato un Modulo 4 comunicando che il direttore Ganesh Moorthy ha acquisito 4.434 unità di azioni ristrette (RSU) di azioni ordinarie il 30/06/2025. Le RSU sono state concesse a costo zero (prezzo $0) e sono classificate sotto il codice transazione “A� (concessione, premio o altra acquisizione).

Il premio maturerà al verificarsi della prima delle seguenti condizioni: (i) il primo anniversario della data di concessione oppure (ii) immediatamente prima dell’assemblea annuale degli azionisti di Ralliant del 2026. Dopo la concessione, la proprietà effettiva totale di Moorthy ammonta a 4.434 azioni, detenute direttamente. Non sono stati segnalati titoli derivati e il modulo è stato firmato dall’avvocato delegato Sarah Johnson il 02/07/2025.

La transazione rappresenta una concessione annuale ordinaria di azioni volta ad allineare gli incentivi del direttore con gli interessi degli azionisti e non indica, di per sé, un cambiamento nelle prospettive finanziarie della società.

Ralliant Corp (RAL) presentó un Formulario 4 informando que el director Ganesh Moorthy adquirió 4,434 unidades de acciones restringidas (RSUs) de acciones comunes el 30/06/2025. Las RSUs se otorgaron sin costo (precio $0) y están clasificadas bajo el código de transacción “A� (concesión, premio u otra adquisición).

La concesión se consolidará al ocurrir la primera de las siguientes condiciones: (i) el primer aniversario de la fecha de otorgamiento o (ii) inmediatamente antes de la reunión anual de accionistas de Ralliant en 2026. Tras la concesión, la propiedad beneficiaria total de Moorthy es de 4,434 acciones, mantenidas directamente. No se reportaron valores derivados y la presentación fue realizada por la apoderada Sarah Johnson el 02/07/2025.

La transacción representa una concesión anual rutinaria de acciones destinada a alinear los incentivos del director con los intereses de los accionistas y no indica, por sí sola, un cambio en las perspectivas financieras de la empresa.

Ralliant Corp (RAL)은 이사 Ganesh Moorthy가 2025� 6� 30일에 보통� 제한 주식 단위(RSU) 4,434주를 취득했다� 내용� 담은 Form 4� 제출했습니다. RSU� 무상(가� $0)으로 부여되었으�, 거래 코드 “A�(부�, 상금 또는 기타 취득)� 분류됩니�.

� 상금은 (i) 부여일로부� 1주년� 되는 � 또는 (ii) Ralliant� 2026� 연례 주주총회 직전 � 먼저 도래하는 시점� 권리가 확정됩니�. 부� � Moorthy� � 실질 소유 주식 수는 4,434�� 직접 보유 중입니다. 파생 증권은 보고되지 않았으며, 제출은 2025� 7� 2� 대리인 Sarah Johnson� 의해 이루어졌습니�.

� 거래� 이사� 인센티브� 주주 이익� 일치시키� 위한 일상적인 연간 주식 부여를 나타내며, � 자체� 회사� 재무 전망 변� 신호� 아닙니다.

Ralliant Corp (RAL) a déposé un formulaire 4 révélant que le directeur Ganesh Moorthy a acquis 4 434 unités d’actions restreintes (RSU) d’actions ordinaires le 30/06/2025. Les RSU ont été attribuées sans coût (prix $0) et sont classées sous le code de transaction « A » (attribution, récompense ou autre acquisition).

La récompense sera acquise au premier des deux événements suivants : (i) le premier anniversaire de la date d’attribution ou (ii) immédiatement avant l’assemblée annuelle des actionnaires de Ralliant en 2026. Après cette attribution, la propriété bénéficiaire totale de Moorthy s’élève à 4 434 actions, détenues directement. Aucun titre dérivé n’a été signalé, et le dépôt a été effectué par la mandataire Sarah Johnson le 02/07/2025.

Cette transaction représente une attribution annuelle de titres courante visant à aligner les incitations du directeur sur les intérêts des actionnaires et ne constitue pas, en soi, un signe de changement dans les perspectives financières de l’entreprise.

Ralliant Corp (RAL) hat ein Formular 4 eingereicht, das offenlegt, dass Direktor Ganesh Moorthy am 30.06.2025 4.434 Restricted Stock Units (RSUs) von Stammaktien erworben hat. Die RSUs wurden kostenfrei (Preis $0) gewährt und sind unter dem Transaktionscode „A� (Gewährung, Auszeichnung oder sonstiger Erwerb) klassifiziert.

Die Zuteilung wird fällig am früheren Zeitpunkt von (i) dem ersten Jahrestag des Gewährungsdatums oder (ii) unmittelbar vor der jährlichen Hauptversammlung der Aktionäre von Ralliant im Jahr 2026. Nach der Gewährung hält Moorthy insgesamt 4.434 Aktien direkt im Besitz. Es wurden keine Derivate gemeldet, und die Einreichung wurde am 02.07.2025 von der Bevollmächtigten Sarah Johnson durchgeführt.

Die Transaktion stellt eine routinemäßige jährliche Aktienzuteilung dar, die darauf abzielt, die Anreize des Direktors mit den Interessen der Aktionäre in Einklang zu bringen, und signalisiert für sich genommen keine Änderung der finanziellen Aussichten des Unternehmens.

Positive
  • Director-shareholder alignment: Equity compensation incentivises board oversight and strategic alignment.
  • Clear vesting schedule: One-year or earlier vesting provides transparency and retains director through the next AGM.
Negative
  • Immaterial size: 4,434 shares is unlikely to influence ownership structure or signal insider confidence.
  • Minor dilution risk: Although minimal, any new share issuance marginally increases shares outstanding.

Insights

TL;DR: Routine RSU grant to director; aligns incentives, negligible financial impact, neutral for valuation.

The Form 4 shows a standard annual equity award�4,434 RSUs—to director Ganesh Moorthy. Because the shares vest within one year or prior to the 2026 AGM, they serve as short-term alignment rather than long-dated compensation. The zero-dollar grant price and small absolute share count indicate minimal cash outlay and negligible dilution. There is no indication of open-market buying or selling, nor any Rule 10b5-1 plan ticked. From a governance standpoint, the award is positive for alignment, yet the scale is too small to alter insider ownership structure meaningfully or to be considered a buy-signal. Overall investment impact is neutral.

Ralliant Corp (RAL) ha presentato un Modulo 4 comunicando che il direttore Ganesh Moorthy ha acquisito 4.434 unità di azioni ristrette (RSU) di azioni ordinarie il 30/06/2025. Le RSU sono state concesse a costo zero (prezzo $0) e sono classificate sotto il codice transazione “A� (concessione, premio o altra acquisizione).

Il premio maturerà al verificarsi della prima delle seguenti condizioni: (i) il primo anniversario della data di concessione oppure (ii) immediatamente prima dell’assemblea annuale degli azionisti di Ralliant del 2026. Dopo la concessione, la proprietà effettiva totale di Moorthy ammonta a 4.434 azioni, detenute direttamente. Non sono stati segnalati titoli derivati e il modulo è stato firmato dall’avvocato delegato Sarah Johnson il 02/07/2025.

La transazione rappresenta una concessione annuale ordinaria di azioni volta ad allineare gli incentivi del direttore con gli interessi degli azionisti e non indica, di per sé, un cambiamento nelle prospettive finanziarie della società.

Ralliant Corp (RAL) presentó un Formulario 4 informando que el director Ganesh Moorthy adquirió 4,434 unidades de acciones restringidas (RSUs) de acciones comunes el 30/06/2025. Las RSUs se otorgaron sin costo (precio $0) y están clasificadas bajo el código de transacción “A� (concesión, premio u otra adquisición).

La concesión se consolidará al ocurrir la primera de las siguientes condiciones: (i) el primer aniversario de la fecha de otorgamiento o (ii) inmediatamente antes de la reunión anual de accionistas de Ralliant en 2026. Tras la concesión, la propiedad beneficiaria total de Moorthy es de 4,434 acciones, mantenidas directamente. No se reportaron valores derivados y la presentación fue realizada por la apoderada Sarah Johnson el 02/07/2025.

La transacción representa una concesión anual rutinaria de acciones destinada a alinear los incentivos del director con los intereses de los accionistas y no indica, por sí sola, un cambio en las perspectivas financieras de la empresa.

Ralliant Corp (RAL)은 이사 Ganesh Moorthy가 2025� 6� 30일에 보통� 제한 주식 단위(RSU) 4,434주를 취득했다� 내용� 담은 Form 4� 제출했습니다. RSU� 무상(가� $0)으로 부여되었으�, 거래 코드 “A�(부�, 상금 또는 기타 취득)� 분류됩니�.

� 상금은 (i) 부여일로부� 1주년� 되는 � 또는 (ii) Ralliant� 2026� 연례 주주총회 직전 � 먼저 도래하는 시점� 권리가 확정됩니�. 부� � Moorthy� � 실질 소유 주식 수는 4,434�� 직접 보유 중입니다. 파생 증권은 보고되지 않았으며, 제출은 2025� 7� 2� 대리인 Sarah Johnson� 의해 이루어졌습니�.

� 거래� 이사� 인센티브� 주주 이익� 일치시키� 위한 일상적인 연간 주식 부여를 나타내며, � 자체� 회사� 재무 전망 변� 신호� 아닙니다.

Ralliant Corp (RAL) a déposé un formulaire 4 révélant que le directeur Ganesh Moorthy a acquis 4 434 unités d’actions restreintes (RSU) d’actions ordinaires le 30/06/2025. Les RSU ont été attribuées sans coût (prix $0) et sont classées sous le code de transaction « A » (attribution, récompense ou autre acquisition).

La récompense sera acquise au premier des deux événements suivants : (i) le premier anniversaire de la date d’attribution ou (ii) immédiatement avant l’assemblée annuelle des actionnaires de Ralliant en 2026. Après cette attribution, la propriété bénéficiaire totale de Moorthy s’élève à 4 434 actions, détenues directement. Aucun titre dérivé n’a été signalé, et le dépôt a été effectué par la mandataire Sarah Johnson le 02/07/2025.

Cette transaction représente une attribution annuelle de titres courante visant à aligner les incitations du directeur sur les intérêts des actionnaires et ne constitue pas, en soi, un signe de changement dans les perspectives financières de l’entreprise.

Ralliant Corp (RAL) hat ein Formular 4 eingereicht, das offenlegt, dass Direktor Ganesh Moorthy am 30.06.2025 4.434 Restricted Stock Units (RSUs) von Stammaktien erworben hat. Die RSUs wurden kostenfrei (Preis $0) gewährt und sind unter dem Transaktionscode „A� (Gewährung, Auszeichnung oder sonstiger Erwerb) klassifiziert.

Die Zuteilung wird fällig am früheren Zeitpunkt von (i) dem ersten Jahrestag des Gewährungsdatums oder (ii) unmittelbar vor der jährlichen Hauptversammlung der Aktionäre von Ralliant im Jahr 2026. Nach der Gewährung hält Moorthy insgesamt 4.434 Aktien direkt im Besitz. Es wurden keine Derivate gemeldet, und die Einreichung wurde am 02.07.2025 von der Bevollmächtigten Sarah Johnson durchgeführt.

Die Transaktion stellt eine routinemäßige jährliche Aktienzuteilung dar, die darauf abzielt, die Anreize des Direktors mit den Interessen der Aktionäre in Einklang zu bringen, und signalisiert für sich genommen keine Änderung der finanziellen Aussichten des Unternehmens.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kiselak Tomas

(Last) (First) (Middle)
C/O VIRIDIAN THERAPEUTICS, INC.
221 CRESCENT STREET, SUITE 103A

(Street)
WALTHAM MA 02453

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $14.47 07/01/2025 A 21,000 (1) 07/01/2035 Common Stock 21,000 $0 21,000 I See Footnote(2)
Explanation of Responses:
1. The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
2. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ Jennifer Tousignant, Attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Ralliant (RAL) shares did Ganesh Moorthy acquire?

Moorthy received 4,434 restricted stock units of common stock.

What was the transaction date reported in the Form 4 filing?

The RSU grant occurred on 06/30/2025.

When do the granted RSUs vest?

They vest on the earlier of one year from grant or immediately before the 2026 annual meeting.

What is Ganesh Moorthy’s total beneficial ownership after the grant?

He now beneficially owns 4,434 RAL shares, held directly.

Was any cash paid for the RSUs?

No. The RSUs were granted at $0 per share.

Does the filing indicate a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox is not marked, so no such plan is reported.
Viridian Therapeutics Inc

NASDAQ:VRDN

VRDN Rankings

VRDN Latest News

VRDN Latest SEC Filings

VRDN Stock Data

1.19B
80.80M
0.12%
114.02%
11.74%
Biotechnology
Services-medical Laboratories
United States
WALTHAM